Authors: Maurizio De Luca Gianni Segato Luca Busetto Franco Favretti Franz Aigner Helmut Weiss Charles de Gheldere Giorgio Gaggiotti Jacques Himpens Jorge Limao Matthias Scheyer Mauro Toppino Ernst L Zurmeyer Giorgio Bottani Heinrich Penthaler
Publish Date: 2014/02/13
Volume: 14, Issue: 1, Pages: S33-S39
Abstract
The Implantable Gastric Stimulator IGS® a pacemakerlike device has been found to be safe and effective to induce and maintain weight loss The LOSS Laparoscopic Obesity Stimulation Survey is a prospective nonrandomized trial which enrolled 69 patients involving 11 investigator centers in 5 European Countries In 19 patients ghrelin was analyzedBetween January 2002 and December 2003 69 patients F/M 49/20 mean age 41 years 18–65 underwent IGS implantation Mean BMI was 41 35–57 mean weight 1150 kg 65–160 and mean excess weight EW 52 kg 13–89 The IGS was actived 30 days after implantation In a subset of 19 patients studied further 0 6 and 12 months appetite and satiety score were evaluated and 0 and 6 months ghrelin profile was analyzedThe mean ± standard error EWL was 86±18 at 1 month 158±23 at 3 months 178±26 at 6 months 210±35 at 10 months and 210±50 at 15 months There were no intraoperative surgical or longterm complications 7 intraoperative gastric penetrations occurred observed by gastroscopy without sequelae 1 patient required a reoperation to remove a retained lead needle In the subset of 19 patients appetite was reduced and postprandial and interprandial satiety was increased after IGS implantation In the 19 patients despite weight reduction ghrelin did not increaseIGS can be implanted laparoscopically with minimal perioperative complications Appetite is reduced and satiety is increased after the implantation Ghrelin levels could be one of the mechanisms explaining weight loss and weight maintenance in IGS patients If weight loss is maintained IGS could be considered a good option for selected patients
Keywords: